Lactoferrin supplement for diabetic kidney disease
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether taking a lactoferrin supplement can help people with type 2 diabetes and chronic kidney disease (stage 3 or 4) by reducing protein in their urine, which is a sign of kidney damage. It may offer a new way to slow the progression of kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have type 2 diabetes and chronic kidney disease at stage 3 or 4, meaning your kidneys are moderately to severely reduced in function.
- You have increased levels of a protein called albumin in your urine, which indicates kidney damage.
- You have been on a stable treatment plan for your diabetes and kidney disease for at least 3 months.
- You are not pregnant or breastfeeding and have a life expectancy of more than one year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called LC-Z300-01 to see if it can reduce protein in the urine of people with diabetic kidney disease. It aims to protect kidney function and slow down kidney damage.
This trial tests if a drug called formoterol (usually used for asthma) can help protect the kidneys in people with type 2 diabetes and early-to-moderate kidney disease. It may offer a new way to slow kidney damage.
This trial studies whether a drug called finerenone can safely and effectively treat kidney disease caused by type 2 diabetes. If you qualify, you would take finerenone while your regular diabetes and blood pressure medications continue unchanged.
This trial tests a medication called finerenone to see if it can lower the amount of protein in your urine, which is a sign of kidney damage. It is for people with type 2 diabetes and chronic kidney disease who are already on standard blood pressure medications.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
This trial tests if a new drug, R3R01, can help reduce protein leaking into the urine in people with diabetic kidney disease. It may offer a new option for managing kidney health.
Hear when a new Diabetic Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.